1012-17-5

Basic information

• Product Name: 3-(4-CHLORO-PHENYL)-2-METHYL-PROPIONIC ACID
• Synonyms: 3-(4-CHLORO-PHENYL)-2-METHYL-PROPIONIC ACID;3-(4-chlorophenyl)-2-methylpropanoic acid
• CAS NO: 1012-17-5
• Molecular Formula: C₁₀H₁₁ClO₂
• Molecular Weight: 198.65
• Mol File: 1012-17-5.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(4-CHLORO-PHENYL)-2-METHYL-PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-CHLORO-PHENYL)-2-METHYL-PROPIONIC ACID(1012-17-5)
• EPA Substance Registry System: 3-(4-CHLORO-PHENYL)-2-METHYL-PROPIONIC ACID(1012-17-5)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 1012-17-5(Hazardous Substances Data)

Usage

Uses

2-(4-Chlorobenzyl)propanoic Acid can be used to inhibit Rho-associated protein kinase to treat diseases.

Upstream product

• 1745-18-2 1-allyl-4-chlorobenzene 
• 104-88-1 4-chlorobenzaldehyde 
• 1202-60-4 3-(4-chlorophenyl)-3-methyl-2-acrylic acid 

Downstream Products

• 117763-47-0 methyl 3-(4-chlorophenyl)-2-methylpropanoate 
• 1346513-46-9 C₂₂H₂₁ClO₂ 

Relevant articles and documents

Carbonylative Transformation of Allylarenes with CO Surrogates: Tunable Synthesis of 4-Arylbutanoic Acids, 2-Arylbutanoic Acids, and 4-Arylbutanals

In this Communication, procedures for the selective synthesis of 4-arylbutanoic acids, 2-arylbutanoic acids, and 4-arylbutanals from the same allylbenzenes have been developed. With formic acid or TFBen as the CO surrogate, reactions proceed selectively and effectively under carbon monoxide gas-free conditions.

Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation

RXRα represents an intriguing and unique target for pharmacologic interventions. We recently showed that Sulindac and a designed analog could bind to RXRα and modulate its biological activity, including inhibition of the interaction of an N-terminally truncated RXRα (tRXRα) with the p85α regulatory subunit of phosphatidylinositol-3-OH kinase (PI3K). Here we report the synthesis, testing and SAR of a series of novel analogs of Sulindac as potential modulators for inhibiting tRXRα-dependent AKT activation. A new compound 30 was identified to have improved biological activity.